Quest Diagnostics Inc said on Tuesday the nationwide surge in coronavirus cases has led to a slight increase in turnaround time for its COVID-19 testing.
Quest Diagnostics can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas.
Fintel reports that on October 8, 2025, Evercore ISI Group maintained coverage of Quest Diagnostics (NYSE:DGX) with a In-Line ...
Florida on Tuesday cut ties with Quest Diagnostics Inc as the medical device maker failed to share the results of nearly 75,000 COVID-19 tests dating back to April with the state health department in ...
Evercore ISI raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $185 and keeps an In Line rating on the shares as the firm ...
Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection-Offered as a laboratory-developed test at ...
The company recently reported that the four-protein test with algorithm-based analysis performed with 83.5 percent sensitivity and 90.3 percent specificity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback